GLP-1市场争夺战:礼来替尔泊肽进医保,国产药如何冲出重围?

药经说
Dec 10, 2025

国家医保局正式公布新版医保、商保目录,让整个医药圈炸开了锅。礼来替尔泊肽以“全球首创双靶点”的姿态进入医保,银诺医药依苏帕格鲁肽α紧随其后,而曾经红极一时的仁会生物贝那鲁肽却黯然退场。更戏剧性的是,恒瑞、石药等本土巨头正携自研新药发起总攻,华东医药、丽珠集团等药企的司美格鲁肽仿制药也正在厉兵秣马,准备分割GLP-1庞大的市场蛋糕。这场涉及众多糖尿病慢病患者,乃至围绕体重控制这一健康需求的重大市场...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10